DRG Market Assessment 보고서

Ulcerative colitis (UC) is a chronic and progressive autoimmune disease that affects the gastrointestinal tract, specifically the colon and rectum. The principal goals of pharmacotherapy for UC are…

The psoriasis therapy market has become increasingly lucrative owing to the growing use of targeted agents. The dominance of TNF-alpha inhibitors and the IL-12/23 inhibitor ustekinumab (Johnson &…

Hemophilia B is a genetic disorder caused by a deficiency in clotting factor IX. Current treatment is dominated by factor IX replacement therapies (in noninhibitor patients) and bypass agents (in…

Age-related macular degeneration (AMD) is a late-onset retinal disease that diminishes central visual acuity due to photoreceptor degeneration in the macula. We expect the historical mainstays of…

Hormonal agents are routinely used in all lines of therapy and thus dominate the treatment of prostate cancer. Next-generation hormonal treatments have expanded beyond metastatic castrate-resistant…

The Emerging Biosimilars Landscape offers extensive coverage of the global biosimilars development landscape. We track over 726 currently available and novel biosimilar products, detailing…

Doublet or triplet chemotherapy alone or in combination with angiogenesis inhibitors remains the cornerstone of treatment for metastatic colorectal cancer. Patients without RAS mutations also…

The multibillion dollar non-Hodgkin’s lymphoma (NHL) / chronic lymphocytic leukemia (CLL) therapy market is dynamic and experiencing substantial growth. The covalent BTK inhibitors ibrutinib (…

Acute coronary syndrome (ACS) encompasses acute ST-elevation myocardial infarction, non-ST-elevation myocardial infarction, and unstable angina. ACS is a significant cause of morbidity and…

The acceptance of Roche / Chugai’s nonfactor bispecific antibody Hemlibra as a key treatment for hemophilia A has changed the treatment landscape. Hemlibra has been transformative for many…

Immune checkpoint inhibitors have transformed many oncology settings since their entry into the marketplace just over a decade ago. They are continuing to advance into earlier lines of therapy,…

The market for metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH), has great untapped potential owing to the disease’s high…